Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir for Acute HCV (PURGE-C)
NCT04042740Phase 2Completed
- Start
- Nov 2019
- Primary completion
- May 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of glecaprevir, pibrentasvir in hepatitis C virus infection. Started Nov 2019; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT04042740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042740.